Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...
Eli Lilly and Company's VERZENIO (abemaciclib) Overview VERZENIO (abemaciclib) is a prescription medication used to treat adults with HR-positive, HER2-negative breast cancer that has metastasized ...
"Billionaire" and "successful hedge fund manager" are titles that carry significant weight on Wall Street. These and others ...
We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...
30-Day Overview Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance ...
Eli Lilly and Company's VERZENIO (abemaciclib) Overview VERZENIO (abemaciclib) is a prescription medication used to treat adults with HR-positive, HER2-negative breast cancer that has metastasized ...
Zacks Investment Research on MSN6d
Eli Lilly Rises 7.5% YTD: Time to Buy, Sell or Hold the Stock?Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...
In the fourth quarter, the company's cancer drug, Verzenio, reported sales of $1.6 billion, up 36% year over year. Eli Lilly's immunosuppressant Taltz racked up revenue of $952 million ...
Eli Lilly and Company (NYSE:LLY) maintains a strong position with Verzenio in breast cancer, currently seeing about 15% of new patient starts going to their competitor in overlapping populations ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback